Beskrivning
Strattera (Atomoxetine) – Non-Stimulant ADHD Medication (Rx)
Strattera (atomoxetine) is a selective norepinephrine reuptake inhibitor (NRI) indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children (≥6 years), adolescents, and adults. Unlike stimulant medications, atomoxetine does not directly increase dopamine release in the reward pathways, which reduces the risk of misuse and dependence.
It works by inhibiting the presynaptic norepinephrine transporter, increasing norepinephrine levels in the brain, particularly in the prefrontal cortex, improving attention, impulse control, and executive function. Its effects build gradually over time rather than producing an immediate stimulant response.
buy Strattera without prescription
We sell over-the-counter Strattera medicine;
snabb, diskret och pålitlig leverans
snabb och säker betalning
handla diskret utan spår
Key Details
- Active Ingredient: Atomoxetine
- Drug Class: Selective norepinephrine reuptake inhibitor (NRI)
- Indications: ADHD (children, adolescents, adults)
- Mechanism of Action: Inhibits norepinephrine reuptake → increased synaptic norepinephrine
- Therapeutic Effects: Improved attention, reduced impulsivity, better behavioral control
- Prescription Status: Prescription-only medicine
Specifikationer
- Dosage Forms: Oral capsules
- Available Strengths: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg
- Administration: Oral, once or twice daily
- Onset of Action: Gradual (1–2 weeks initial, full effect 4–6 weeks)
- Half-Life: ~5 hours (extensive metabolizers), up to ~24 hours (poor metabolizers)
- Metabolism: Hepatic via CYP2D6
- Excretion: Primarily renal (as metabolites)
- Storage: Room temperature
Dosage & Administration
- Children/adolescents: Weight-based dosing
- Adults: Typically start at ~40 mg/day, increasing to ~80 mg/day
- May be taken once daily or divided into two doses
- Can be taken with or without food
- Dose adjustments may be required for CYP2D6 metabolism differences
Compatibility / Suitable Use
- Patients with ADHD who require a non-stimulant option
- Individuals with a history of substance misuse
- Patients who do not tolerate stimulant medications
- Suitable for long-term management under medical supervision
Läkemedelsinteraktioner
- CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): Increased atomoxetine levels
- MAOIs: Contraindicated
- Antihypertensives: May reduce effectiveness
Why Choose Strattera?
Strattera offers a non-stimulant, once-daily ADHD treatment with a lower risk of misuse compared to stimulant medications. Its targeted action on norepinephrine makes it a valuable option for patients requiring a steady, long-term approach to ADHD management.